Biogen (BIIB) Accounts Payables (2009 - 2026)

Biogen's Accounts Payables history runs 18 years deep, the most recent figure standing at $358.5 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 8.43% year-over-year to $358.5 million; the TTM figure through Mar 2026 stood at $358.5 million (down 8.43% YoY), while the FY2025 annual figure was $432.0 million, up 1.84% from the prior year.
• Accounts Payables was $358.5 million for Q1 2026 at Biogen, down from $432.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $491.5 million in Q4 2022 to a low of $354.5 million in Q2 2024.
• Historically, Accounts Payables has averaged $416.5 million across 5 years, with a median of $413.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables advanced 23.2% in 2023, then dropped 21.21% in 2024.
• A 5-year view of Accounts Payables shows it stood at $491.5 million in 2022, then slipped by 17.95% to $403.3 million in 2023, then gained by 5.18% to $424.2 million in 2024, then grew by 1.84% to $432.0 million in 2025, then retreated by 17.01% to $358.5 million in 2026.
• The last three Accounts Payables figures came in at $358.5 million (Q1 2026), $432.0 million (Q4 2025), and $413.1 million (Q3 2025), per Business Quant data.